Back to Search Start Over

Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects

Authors :
Yan Jiang
Carolina Muguruza
Daisuke Ibi
Carlos R. Escalante
Maryum K. Ijaz
Daniel J. Christoffel
Schahram Akbarian
Alexey Kozlenkov
Scott J. Russo
Nebojsa Kezunovic
Vishaka Santosh
Jeremy Seto
Javier González-Maeso
Terrell Holloway
Supriya A Gaitonde
Luis F. Callado
J. Javier Meana
Mario de la Fuente Revenga
José L. Moreno
Stella Dracheva
Mitsumasa Kurita
Grace E. Mosley
George W. Huntley
Juan F. López-Giménez
Aintzane García-Bea
Yongchao Ge
Justin M. Saunders
Japan Society for the Promotion of Science
National Institutes of Health (US)
Ministerio de Economía y Competitividad (España)
European Commission
Eusko Jaurlaritza
Uehara Memorial Foundation for International Students
Icahn School of Medicine at Mount Sinai
Source :
Digital.CSIC. Repositorio Institucional del CSIC, instname
Publication Year :
2017

Abstract

Ibi, Daisuke et al.<br />Antipsychotic drugs remain the standard for schizophrenia treatment. Despite their effectiveness in treating hallucinations and delusions, prolonged exposure to antipsychotic medications leads to cognitive deficits in both schizophrenia patients and animal models. The molecular mechanisms underlying these negative effects on cognition remain to be elucidated. Here we demonstrate that chronic antipsychotic drug exposure increases nuclear translocation of NF-κB in both mouse and human frontal cortex, a trafficking event triggered via 5-HT-receptor-dependent downregulation of the NF-κB repressor IκBα. This upregulation of NF-κB activity led to its increased binding at the Hdac2 promoter, thereby augmenting Hdac2 transcription. Deletion of HDAC2 in forebrain pyramidal neurons prevented the negative effects of antipsychotic treatment on synaptic remodeling and cognition. Conversely, virally mediated activation of NF-κB signaling decreased cortical synaptic plasticity via HDAC2. Together, these observations may aid in developing therapeutic strategies to improve the outcome of schizophrenia treatment.<br />NIH R01 MH084894 (J.G.M.), NIH R01 MH111940 (J.G.M.), Dainippon Sumitomo Pharma (J.G.M.), NARSAD (J.G.M.), the Japan Society for the Promotion of Science (JSPS) 15H06719 and 16K19786 (D.I.), NIH R01 MH104491 (G.W.H.), NIH R01 MH086509 (S.A.), NIH P50 MH096890 (S.A.), MINECO/ERDF SAF2009-08460 (J.J.M. and L.F.C.), SAF2013-45084R (J.J.M. and L.F.C.), Basque Government IT616-13 (J.J.M.), NIH R21 MH103877 (S.D.) and NIH R01 MH090264 (S.J.R.) participated in the funding of this study. RNA-seq analysis was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai and the NIH infrastructure grant S10OD018522. C.M. and A.G.B. were recipients of a postdoctoral and a predoctoral fellowship from the Basque Government, respectively. D.I. was a recipient of postdoctoral fellowships from JSPS (Young Scientists JSPS 23-3454) and the Uehara Memorial Foundation.

Details

ISSN :
15461726 and 20090846
Volume :
20
Issue :
9
Database :
OpenAIRE
Journal :
Nature neuroscience
Accession number :
edsair.doi.dedup.....66464623ccb19b82f6f131f694dde974